QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ADPT

QT61Adaptive Biotechnologies Corporation
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
17.53
+0.75+4.47%
OverviewShort InterestFilings
ADPTQT61Adaptive Biotechnologies Corporation·NASDAQ
OverviewShort InterestFilings
17.53+4.47%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-0.33
Insider Own5.92%
Shs Outstand160.04M
Perf Week-6.41%
Market Cap2.69BForward P/E-EPS next Y-0.25Insider Trans-1.10%Shs Float-Perf Month35.26%
Enterprise Value2.82BPEG-EPS next Q-0.13Inst Own-Short Float-Perf Quarter29.85%
Income-51025228.00P/S9.09EPS this Y-39.77%Inst Trans-Short Ratio-Perf Half Y10.04%
Sales295.41MP/B12.06EPS next Y46.61%ROA-9.82%Short Interest-Perf YTD7.94%
Book/sh1.40P/C-EPS next 5Y-ROE-24.26%52W High20.76 -15.56%Perf Year72.88%
Cash/sh1.36P/FCF-EPS past 3/5Y-ROIC-10.78%52W Low9.96 76.00%Perf 3Y-
Dividend Est.-EV/EBITDA-127.83Sales past 3/5Y14.40% 23.10%Gross Margin75.26%Volatility7.45% 5.20%Perf 5Y-
Dividend TTM-EV/Sales9.53EPS Y/Y TTM50.00%Oper. Margin-15.82%ATR (14)1.18Perf 10Y-
Dividend Ex-Date-Quick Ratio3.22Sales Y/Y TTM65.36%Profit Margin-16.82%RSI (14)59.98Recom2.25
Dividend Gr. 3/5Y-Current Ratio3.35EPS Q/Q35.00%SMA208.26%Beta1.88Target Price21.33
Payout0.00%Debt/Eq0.96Sales Q/Q36.54%SMA5018.44%Rel Volume1.69Prev Close16.78
Employees619LT Debt/Eq1.19EarningsAug 04SMA20013.39%Avg Volume2.30MPrice17.53
IPO DateJun 27, 2019Option/ShortYes / YesEPS/Sales Surpr.18.75% 16.39%Net Debt/EBITDA-5.93Volume3,881,495Change4.47%
Analyst Ratings
DateActionAnalystRatingTarget
Feb-06-26ReiteratedPiper SandlerOverweight$20 → $21
Feb-06-26ReiteratedBTIGBuy$5.00 → $22
Jan-26-26ReiteratedGuggenheimBuy$20 → $21
Dec-01-25ReiteratedMorgan StanleyEqual Weight$18 → $21
Oct-15-25ReiteratedPiper SandlerOverweight$14 → $20
Sep-30-25ReiteratedGuggenheimBuy$20
Mar-21-25UpgradeGoldman SachsNeutral → Buy
Apr-04-24ReiteratedBTIGBuy$5.00
Dec-21-22UpgradePiper SandlerNeutral → Overweight$12 → $14
Aug-17-22ReiteratedPiper SandlerNeutral$7.50 → $12
Latest News
Jun-17-26
Jun-17-2601:21PM
Adaptive Biotechnologies Business Separation May Unlock Greater ValueBenzinga
11:22AM
BTIG Reiterates Buy on Adaptive Biotechnologies, Maintains $22 Price TargetBenzinga
06:03AM
Adaptive Biotechnologies Prices $300M Upsized Convertible Notes Offering (Up From $250M)Benzinga
Jun-16-26
Jun-16-2610:42AM
Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine BusinessesBenzinga
08:49AM
Stock Market Today: S&P 500, Nasdaq Futures Fall, Dow Gains Amid US-Iran Deal— SpaceX, Dave And Buster's, Western Digital In Focus (UPDATED)Benzinga
08:05AM
Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionBenzinga
05:23AM
Why High Tide Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving PremarketBenzinga
02:06AM
John Wiley & Sons, Dave and Buster's Entertainment And 3 Stocks To Watch Heading Into TuesdayBenzinga
Jun-15-26
Jun-15-2604:14PM
Adaptive Biotechnologies Plans Separation Of MRD And Immune Medicine Businesses, Targets Preferred Path By Year-End 2026Benzinga
04:14PM
Adaptive Biotechnologies Launches $250M Convertible Senior Notes Offering Due 2031 To Repay OrbiMed Debt, Fund Share Repurchases, And Support Growth InitiativesBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue296277179
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A737172
Gross Profit222206107
Selling, General and Administrative Excl. Other173167158
Research and Development9494103
Other Operating Expense228
Operating Income-47-57-163
Interest Expense121212
Unusual Expense
———
Non-Operating Income (Expense)-7-9-15
Net Income Before Taxes-50-59-160
Income Taxes
000
Consolidated Net Income-50-59-159
Net Income From Continuing Operations-50-59-160
Net Income-50-59-159
EPS (Recurring)-0.33-0.39-1.08
EPS (Basic, Before Extraordinaries)-0.33-0.39-1.08
EPS (Diluted)-0.33-0.39-1.08
EBITDA-21-30-129
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio9.248.91—
Gross Margin75.0074.3759.78
Operating Margin-15.88-20.58-91.06
Net Margin-16.89-21.30-88.83
Shares Outstanding156152147
Market Capitalization2,7352,468—
Operating Lease Expense
———
Insider Trading Volume
$18.90$17.20$15.51$13.81$12.11● Close Price0.00M7.48M14.96M22.44M29.91MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
ROBINS HARLAN SChief Scientific OfficerJun 16 '26Sale18.016,160110,9421,405,898Jun 17 12:00 AM
ROBINS HARLAN SChief Scientific OfficerJun 15 '26Sale17.37100,0001,737,0001,412,058Jun 17 12:00 AM
BOBULSKY SUSANChief Commercial Officer, MRDJun 11 '26Sale19.005,00095,000411,775Jun 15 12:00 AM
LO FRANCISChief People OfficerJun 04 '26Option Exercise8.8539,042345,594290,675Jun 08 12:00 AM
BOBULSKY SUSANChief Commercial Officer, MRDJun 04 '26Sale18.0011,000198,000416,775Jun 08 12:00 AM
LO FRANCISChief People OfficerJun 04 '26Sale17.4939,741695,070250,934Jun 08 12:00 AM
PISKEL KYLEChief Financial OfficerMay 18 '26Sale13.043,11540,620256,725May 20 12:00 AM
RUBINSTEIN JULIEPresident and COOApr 27 '26Sale14.2319,037270,897377,802Apr 29 12:00 AM
RUBINSTEIN JULIEPresident and COOApr 27 '26Option Exercise8.4629,414248,842396,839Apr 29 12:00 AM
RUBINSTEIN JULIEPresident and COOApr 24 '26Option Exercise8.4629,444249,096401,192Apr 24 12:00 AM
RUBINSTEIN JULIEPresident and COOApr 24 '26Sale14.0219,060267,221382,132Apr 24 12:00 AM
RUBINSTEIN JULIEPresident and COOApr 23 '26Option Exercise8.4629,444249,096405,530Apr 24 12:00 AM
RUBINSTEIN JULIEPresident and COOApr 23 '26Sale13.7419,060261,884386,470Apr 24 12:00 AM
RUBINSTEIN JULIEPresident and COOApr 22 '26Option Exercise8.4629,444249,096409,868Apr 24 12:00 AM
RUBINSTEIN JULIEPresident and COOApr 22 '26Sale14.1319,060269,318390,808Apr 24 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR